PTPN11 and head and neck squamous cell carcinoma: These data are consistent with the correlation we found between EGFR and GAB1 in the Depmap CRISPR/Cas9 screening data and fits the picture that targeting GAB1 complexes—for instance, by targeting SHP2—may be a more potent therapy for HNSCC than EGFR inhibition.